SFRP1 and non-small cell lung carcinoma: However, increased SFRP1 and SFRP2 methylation levels were more frequently detected in male NSCLC patients (SFRP1: 5.81% versus 3.06%, P = 0.043; SFRP2: 28.67% versus 8.38%, P = 0.007, respectively).